The EO treatment of AD mice could strongly reduce the NLRP3-inflammasome signaling pathway and pyroptosis markers as indicated by reduced NLRP3, caspase-1, ASC and cleaved-gasdermin D at the mRNA and protein level. This evidence concerns the gene GSDMD and Alzheimer disease.